
CHMP Recommends Third Indication for Bayer’s Nubeqa in Advanced Prostate Cancer Patients
CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…












